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persistent asthma in Spain is going to represent a savings of 11€
millions in the Spanish National Pharmaceutical budget in the
next 5 years.
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OBJECTIVES: Omalizumab is a monoclonal antibody indicated
for treatment of severe persistent allergic asthma inadequately
controlled despite an optimal controller therapy. The purpose of
this study is to determine a cost-effectiveness analysis of omali-
zumab vs ST in the treatment of severe asthma in Mexico.
METHODS: A cost-effectiveness analysis was performed based
on a six-state Markov model. The transition probabilities and the
response rate were obtained from a meta-analysis. The pattern of
resource use was derived from the Second Mexican Consensus of
Asthma (steps 4 and 5). Unit costs of resources and medications
were obtained from medical care in IMSS 2004, and were trans-
formed to current prices using inﬂation rates. The cost of oma-
lizumab was provided by the laboratory. The time horizon was
one year. A discount rate was not required. The model was
calibrated. The effectiveness rate was the number of days free
from exacerbations. A one-way and two-way probabilistic sen-
sitivity analysis was used using a Tornado chart. A stochastic
optimization analysis was performed with 500 runs involving
100,000 Monte Carlo iterations; the budget and percent use of
omalizumab were the model restrictions. Maximization of incre-
mental net beneﬁts was obtained with the model. RESULTS: The
expected cost per patient was $14,940 USD ($502) with oma-
lizumab, while this ﬁgure was $6,144 USD ($207) for ST. The
expected effectiveness was 333 (3) and 306 (6) days without
exacerbation/year, respectively. The stochastic optimization
maximized the net incremental beneﬁts with a ratio of 42% for
omalizumab, and 58% for the standard therapy. The sensitivity
analysis was robust in the conclusions of the basic study. CON-
CLUSION: Omalizumab is a cost-effective therapy in the
management of patients with severe asthma. The ratio for oma-
lizumab acquisition with stochastic optimization was 42%.
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OBJECTIVES: To analyze cost-effectiveness of budesonid/
formoterol versus typical practice for treating asthma in Russian
health care system. METHODS: Open, randomized, compara-
tive trial was carried out in 16 cities of Russia. 300 outpatients
were observed during 6 months. A total of 150 from them
were prescribed budesonid/formoterol, 150 continued anti-
inﬂammatory therapy prescribed earlier (typical practice of treat-
ing patients). IN all, 103 patients from them received inhaled
corticosteroids 800–1600 mcg as monotherapy, 21 patient
received inhaled corticosteroids in a combination with long-
acting 2-agonists and 26 patient received cromons. The degree of
restriction of physical activity, frequency of day time and night
attacks were estimated on a scale in 5 points (0-absence of the
infringements, 2–4-moderate and heavy infringements). Applica-
tion of udesonid/formoterol has shown the best results by all
criteria of clinical efﬁciency. RESULTS: The increase of FEV1 by
the end of research (20% on a median) was signiﬁcantly greater
in group of abudesonid/formoterol than in control group (11%).
Cost of treatment (cost of drugs and physician visits) was some-
what higher in budesonid/formoterol group. Average cost-
effectiveness ratio showed that the cost per % increase of FEV1in
group of budesonid/formoterol (484,08 rubles for the 1 month,
1742.68 rubles for 6 months) was lower than in group of com-
parison (1131.56 rubles and 2468.86 rubles). Cost per patient
with absence of moderate or heavy infringements on all used
scales at the end of study also was lower in the ﬁrst group
(9220.54 rubles for the 1 month; 44,684.15 rubles for 6 months)
than in the second group (11,911.13 rubles, 59,037.78 rubles).
CONCLUSION: Budesonid/formoterol is cost-effective in treat-
ment of bronchial asthma.
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OBJECTIVES: A large scale database analysis was undertaken
comparing resource use in UK primary care patients receiving
inhaled steroids via MDI and BOI. The aim was to compare
resource use over a two-year period of patients receiving inhaled
beclometasone via MDI, with patients utilising BOI.
METHODS: Data was extracted from Din-Link patient-level
databases to compare resource utilisation over 24 months in
patients receiving BOI with those on standard MDI. Entry crite-
ria were: 1) Diagnosis of asthma; 2) Receiving beclometasone via
MDI; and 3) No other preventer medication. Index event was
change to a different MDI or BOI. Key measures included annua-
lised average costs of: i) Primary care consultation for asthma; ii)
Anti-asthma prescriptions; iii) Spacer devices; and iv) Hospital
referral and admissions for asthma. RESULTS: Primary care
medication costs for child patients were 108.62 (BAI) versus
77.23(MDI) and for adults were 79.35 (BAI) versus 92.76
(MDI). Non-medication resource use for child patients over the
period was: GP consultation (63.00 BAI vs 102.68 MDI);
outpatient attendance (18.43 BAI vs 22.62 MDI); hospital
admissions (0.00 BAI vs 15.46 MDI). Non-medication
resource use for adult patients was: GP consultation (82.75
BAI vs 114.20 MDI); outpatient attendance (10.75 BAI vs
12.30 MDI); hospital admissions (28.35 BAI vs 21.39
MDI). Total asthma costs over the two year period for BAI
patients were 190.05 (children) and 201.20 (adults). Com-
parative ﬁgures for MDI patients were 217.99 (children) and
240.56 (adults). CONCLUSION: The additional acquisition
cost associated with BOI appears to be offset by enhanced clinical
effectiveness. A trend in cost effectiveness emerged in favour of
BOI versus the equivalent MDI for both children and adults.
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OBJECTIVES: For patients with grass pollen induced rhinocon-
junctivitis where immunotherapy is appropriate there are cur-
rently two medically approved treatment alternatives available in
Finland and Norway: Subcutaneous Immunotherapy (SCIT) and
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